Care
home residents and workers
80+
and health/social care workers
All
those 75+
All
those 70+
All
those 65+
High-
risk adults under 65
Moderate-
risk adults under 65
All
those 60+
All
those 55+
All
those 50+
Rest
of population
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
% of total population by priority group (based on U.K. priority grouping)
% of population with vaccine-induced immunity by deal under scenario A assumptions:
Moderna
BioNTech/Pfizer
Johnson & Johnson (Janssen)
Oxford/AstraZeneca
Novavax
Sanofi/GSK
Valneva
Total across all deals